ANI Pharmaceuticals ANIP EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ANI Pharmaceuticals's EPS (diluted)?
- ANI Pharmaceuticals (ANIP) reported EPS (diluted) of $1.28 in Q1 2026.
- How has ANI Pharmaceuticals's EPS (diluted) changed year-over-year?
- ANI Pharmaceuticals's EPS (diluted) increased by 85.5% year-over-year, from $0.69 to $1.28.
- What is the long-term trend for ANI Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's EPS (diluted) has grown at a -0.4% compound annual growth rate (CAGR), from -$3.40 to $3.35.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.